Algeria has adopted a therapeutic protocol using hydroxychloroquine(HCQ)as a first-line treatment for patients with coronavirus disease 2019(COVID-19).The administration of HCQ must be accompanied by appropriate cardi...Algeria has adopted a therapeutic protocol using hydroxychloroquine(HCQ)as a first-line treatment for patients with coronavirus disease 2019(COVID-19).The administration of HCQ must be accompanied by appropriate cardiac and therapeutic pharmacological monitoring to avoid side effects and toxicity.This work is a retrospective descriptive study aiming to estimate the HCQ levels of COVID-19 patients.HCQ concentrations in blood samples from COVID-19 patients were determined using high performance liquid chromatography with diode array detector(HPLC-DAD)after liquid-liquid extraction of plasma.The coefficient of determination(r2)of this method was 0.9999.The limits of quantification and detection were 0.05 mg/L and 0.02 mg/L,respectively,with coefficients of variance less than 6%.Patient monitoring was performed following recommendations for the therapeutic pharmacological monitoring of HCQ in patients treated for SARS-CoV-2(COVID-19)infection validated by the coordinated action(AC43)of the National Agency for Research on AIDS and Viral Hepatitis(ANRS)and Therapeutic Pharmacological Monitoring and Personalization of Treatments(STP-PT)group.A total of 267 blood samples from 240 patients were analyzed,49%for males and 51%for females.More than a third of the patients were 60-80 years old.The majority(68%)of the HCQ concentrations were between 0.1 and 1 mg/L.Additionally,more than 20%were between 0.05 and 0.1 mg/L,while only 7.5%were less than 0.05mg/L and 1.5%were greater than 1 mg/L.In summary,patients with COVID-19 showed a good tolerance to HCQ in the majority of cases.展开更多
文摘Algeria has adopted a therapeutic protocol using hydroxychloroquine(HCQ)as a first-line treatment for patients with coronavirus disease 2019(COVID-19).The administration of HCQ must be accompanied by appropriate cardiac and therapeutic pharmacological monitoring to avoid side effects and toxicity.This work is a retrospective descriptive study aiming to estimate the HCQ levels of COVID-19 patients.HCQ concentrations in blood samples from COVID-19 patients were determined using high performance liquid chromatography with diode array detector(HPLC-DAD)after liquid-liquid extraction of plasma.The coefficient of determination(r2)of this method was 0.9999.The limits of quantification and detection were 0.05 mg/L and 0.02 mg/L,respectively,with coefficients of variance less than 6%.Patient monitoring was performed following recommendations for the therapeutic pharmacological monitoring of HCQ in patients treated for SARS-CoV-2(COVID-19)infection validated by the coordinated action(AC43)of the National Agency for Research on AIDS and Viral Hepatitis(ANRS)and Therapeutic Pharmacological Monitoring and Personalization of Treatments(STP-PT)group.A total of 267 blood samples from 240 patients were analyzed,49%for males and 51%for females.More than a third of the patients were 60-80 years old.The majority(68%)of the HCQ concentrations were between 0.1 and 1 mg/L.Additionally,more than 20%were between 0.05 and 0.1 mg/L,while only 7.5%were less than 0.05mg/L and 1.5%were greater than 1 mg/L.In summary,patients with COVID-19 showed a good tolerance to HCQ in the majority of cases.
